# European Group for Research In Schizophrenia: Phase 3 study withdrawn (Schizophrenia, Psychosis)

**Score:** 65/100

| Field | Value |
|---|---|
| Sponsor | European Group for Research In Schizophrenia |
| Sponsor type | Academic and hospital |
| Study | A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia |
| NCT ID | NCT07084831 |
| Phase | Phase 3 |
| Status | withdrawn |
| Conditions | Schizophrenia; Psychosis; Cognitive Impairment |
| Intervention types | drug |
| Site countries | Austria, Belgium, Czechia, Denmark, Germany, Hungary, Israel, Italy, Netherlands, Spain |
| Posted | 2025-07-25 |
| Planned start | 2027-01-01 |
| Event | Withdrawn before enrolling |
| Event date | 2026-10-30 |
| Last update posted | 2026-10-30 |

## Why this score
- Posted in the last two weeks.
- Stopped early: budget and sites freed up.
- Phase 3: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07084831). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.